Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study.
Hepatocellular carcinoma
Radiofrequency ablation
Subphrenic location
Transarterial chemoembolization
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
10
08
2021
accepted:
20
09
2021
revised:
17
09
2021
pubmed:
29
9
2021
medline:
17
11
2021
entrez:
28
9
2021
Statut:
ppublish
Résumé
To compare therapeutic outcomes of combined transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) treatment for small hepatocellular carcinoma (HCC) in subphrenic versus nonsubphrenic locations by propensity score matching. This retrospective study included 293 patients with single HCC (≤ 3 cm) ineligible for ultrasound-guided RFA who received iodized oil TACE and subsequent RFA between June 2010 and January 2017. The patients were divided into two groups according to the tumor location: subphrenic (n = 99) and nonsubphrenic (n = 194). Subphrenic HCC was defined as a tumor abutting the diaphragm. Local tumor progression (LTP) and overall survival (OS) rates were compared by propensity score matching. Procedure-related complications were also assessed. Matching yielded 93 matched pairs of patients. In the matched cohorts, cumulative 1-, 3-, and 5-year LTP rates were 5.4%, 12.1%, and 12.1% in the subphrenic group and 1.1%, 7.5%, and 8.6% in the nonsubphrenic group, respectively, with no significant differences (p = 0.278). Corresponding OS rates were 100%, 80.2%, and 71.3% in the subphrenic group and 97.9%, 88.1%, and 75.6% in the nonsubphrenic group, respectively, with no significant differences (p = 0.308). The subphrenic location was not a significant risk factor for LTP and OS in multivariate analysis. There were no significant differences in complication rates between the two groups (p > 0.05). The therapeutic outcomes of combined TACE and RFA for small subphrenic HCC were similar to those for nonsubphrenic HCC. The combination therapy seems to be an effective and safe method in treating small subphrenic HCC.
Identifiants
pubmed: 34581928
doi: 10.1007/s00261-021-03291-6
pii: 10.1007/s00261-021-03291-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5735-5745Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bruix J, Sherman M, American Association for the Study of Liver D (2011) Management of hepatocellular carcinoma: an update. Hepatology 53 (3):1020-1022. https://doi.org/10.1002/hep.24199
doi: 10.1002/hep.24199
Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology international 11 (4):317-370. https://doi.org/10.1007/s12072-017-9799-9
doi: 10.1007/s12072-017-9799-9
pubmed: 28620797
Kim PN, Choi D, Rhim H, Rha SE, Hong HP, Lee J, Choi JI, Kim JW, Seo JW, Lee EJ, Lim HK (2012) Planning ultrasound for percutaneous radiofrequency ablation to treat small (</= 3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: a multicenter prospective study to assess factors affecting ultrasound visibility. J Vasc Interv Radiol 23 (5):627-634. https://doi.org/10.1016/j.jvir.2011.12.026
doi: 10.1016/j.jvir.2011.12.026
pubmed: 22387030
Ding H, Su M, Zhu C, Wang L, Zheng Q, Wan Y (2017) CT-guided versus laparoscopic radiofrequency ablation in recurrent small hepatocellular carcinoma against the diaphragmatic dome. Scientific reports 7:44583. https://doi.org/10.1038/srep44583
doi: 10.1038/srep44583
pubmed: 28291254
pmcid: 5349557
Kato T, Yamagami T, Hirota T, Matsumoto T, Yoshimatsu R, Nishimura T (2008) Transpulmonary radiofrequency ablation for hepatocellular carcinoma under real-time computed tomography-fluoroscopic guidance. Hepato-gastroenterology 55 (85):1450-1453
pubmed: 18795709
Podnos YD, Henry G, Ortiz JA, Ji P, Cooke J, Cao S, Imagawa DK (2001) Laparoscopic ultrasound with radiofrequency ablation in cirrhotic patients with hepatocellular carcinoma: technique and technical considerations. The American surgeon 67 (12):1181-1184
pubmed: 11768826
Rhim H, Lim HK, Kim YS, Choi D (2008) Percutaneous radiofrequency ablation with artificial ascites for hepatocellular carcinoma in the hepatic dome: initial experience. AJR American journal of roentgenology 190 (1):91-98. https://doi.org/10.2214/AJR.07.2384
doi: 10.2214/AJR.07.2384
pubmed: 18094298
Song KD, Lee MW, Rhim H, Cha DI, Chong Y, Lim HK (2013) Fusion imaging-guided radiofrequency ablation for hepatocellular carcinomas not visible on conventional ultrasound. AJR American journal of roentgenology 201 (5):1141-1147. https://doi.org/10.2214/AJR.13.10532
doi: 10.2214/AJR.13.10532
pubmed: 24147489
Toyoda M, Kakizaki S, Horiuchi K, Katakai K, Sohara N, Sato K, Takagi H, Mori M, Nakajima T (2006) Computed tomography-guided transpulmonary radiofrequency ablation for hepatocellular carcinoma located in hepatic dome. World journal of gastroenterology 12 (4):608-611
doi: 10.3748/wjg.v12.i4.608
Song KD, Lim HK, Rhim H, Lee MW, Kang TW, Paik YH, Kim JM, Joh JW (2019) Hepatic resection vs percutaneous radiofrequency ablation of hepatocellular carcinoma abutting right diaphragm. World J Gastrointest Oncol 11 (3):227-237. https://doi.org/10.4251/wjgo.v11.i3.227
doi: 10.4251/wjgo.v11.i3.227
pubmed: 30918595
pmcid: 6425331
Kim JH, Kim PN, Won HJ, Shin YM (2013) Percutaneous radiofrequency ablation with internally cooled versus internally cooled wet electrodes for small subphrenic hepatocellular carcinomas. J Vasc Interv Radiol 24 (3):351-356. https://doi.org/10.1016/j.jvir.2012.11.025
doi: 10.1016/j.jvir.2012.11.025
pubmed: 23433411
Sugimori K, Nozawa A, Morimoto M, Shirato K, Kokawa A, Saito T, Numata K, Tanaka K (2005) Extension of radiofrequency ablation of the liver by transcatheter arterial embolization with iodized oil and gelatin sponge: results in a pig model. J Vasc Interv Radiol 16 (6):849-856. https://doi.org/10.1097/01.RVI.0000157780.44868.78
doi: 10.1097/01.RVI.0000157780.44868.78
pubmed: 15947049
Hyun D, Cho SK, Shin SW, Park KB, Lee SY, Park HS, Do YS (2018) Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naive hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes. Acta Radiol 59 (7):773-781. https://doi.org/10.1177/0284185117735349
doi: 10.1177/0284185117735349
pubmed: 29034691
Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K (2010) Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 116 (23):5452-5460. https://doi.org/10.1002/cncr.25314
doi: 10.1002/cncr.25314
pubmed: 20672352
Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, Kim PN (2011) Medium-sized (3.1–5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol 18 (6):1624–1629. https://doi.org/10.1245/s10434-011-1673-8
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L (2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of hepatology 69 (1):182-236. https://doi.org/10.1016/j.jhep.2018.03.019
doi: 10.1016/j.jhep.2018.03.019
Korean Liver Cancer A, National Cancer Center GK (2019) 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol 20 (7):1042-1113. https://doi.org/10.3348/kjr.2019.0140
doi: 10.3348/kjr.2019.0140
Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K (2009) Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology 252 (3):905-913. https://doi.org/10.1148/radiol.2523081676
doi: 10.1148/radiol.2523081676
pubmed: 19567647
Lee MW, Kang D, Lim HK, Cho J, Sinn DH, Kang TW, Song KD, Rhim H, Cha DI, Lu DSK (2020) Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 30 (4):2391-2400. https://doi.org/10.1007/s00330-019-06575-0
doi: 10.1007/s00330-019-06575-0
pubmed: 31900708
Lee SY, Hyun D, Cho SK, Shin SW, Jung SH, Chi SA (2018) Iodized Oil Transarterial Chemoembolization and Radiofrequency Ablation for Small Periportal Hepatocellular Carcinoma: Comparison with Nonperiportal Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 41 (1):120-129. https://doi.org/10.1007/s00270-017-1783-1
doi: 10.1007/s00270-017-1783-1
pubmed: 28924943
Yamakado K, Nakatsuka A, Takaki H, Sakurai H, Isaji S, Yamamoto N, Shiraki K, Takeda K (2010) Subphrenic versus nonsubphrenic hepatocellular carcinoma: combined therapy with chemoembolization and radiofrequency ablation. AJR American journal of roentgenology 194 (2):530-535. https://doi.org/10.2214/AJR.09.2917
doi: 10.2214/AJR.09.2917
pubmed: 20093620
Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, Takeda T, Yoneda N, Notsumata K, Toya D, Tanaka N, Mitsui T (2007) Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil. J Vasc Interv Radiol 18 (3):365-376. https://doi.org/10.1016/j.jvir.2006.12.004
doi: 10.1016/j.jvir.2006.12.004
pubmed: 17377182
Shin SW (2009) The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 10 (5):425-434. https://doi.org/10.3348/kjr.2009.10.5.425
doi: 10.3348/kjr.2009.10.5.425
pubmed: 19721826
pmcid: 2731859
Inoue T, Minami Y, Chung H, Hayaishi S, Ueda T, Tatsumi C, Takita M, Kitai S, Hatanaka K, Ishikawa E, Yada N, Hagiwara S, Ueshima K, Kudo M (2010) Radiofrequency ablation for hepatocellular carcinoma: assistant techniques for difficult cases. Oncology 78 Suppl 1:94-101. https://doi.org/10.1159/000315236
doi: 10.1159/000315236
pubmed: 20616590
Rhim H, Lim HK (2009) Radiofrequency ablation for hepatocellular carcinoma abutting the diaphragm: the value of artificial ascites. Abdom Imaging 34 (3):371-380. https://doi.org/10.1007/s00261-008-9408-4
doi: 10.1007/s00261-008-9408-4
pubmed: 18463915
Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baere T, Dodd GD, 3rd, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee FT, Jr., Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN, International Working Group on Image-Guided Tumor A, Interventional Oncology Sans Frontieres Expert P, Technology Assessment Committee of the Society of Interventional R, Standard of Practice Committee of the C, Interventional Radiological Society of E (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol 25 (11):1691–1705 e1694. https://doi.org/10.1016/j.jvir.2014.08.027
Sacks D, McClenny TE, Cardella JF, Lewis CA (2003) Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 14 (9 Pt 2):S199-202. https://doi.org/10.1097/01.rvi.0000094584.83406.3e
doi: 10.1097/01.rvi.0000094584.83406.3e
Gray R (1992) Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Am Stat Assoc 87:942-951
doi: 10.1080/01621459.1992.10476248
Fine J, Gray R (1999) A proportional hazards model for the subdistribution of a competiting risk. J Am Stat Assoc 94:496-509
doi: 10.1080/01621459.1999.10474144
Yamanaka T, Yamakado K, Takaki H, Nakatsuka A, Shiraki K, Hasegawa H, Takei Y, Takeda K (2012) Ablative zone size created by radiofrequency ablation with and without chemoembolization in small hepatocellular carcinomas. Jpn J Radiol 30 (7):553-559. https://doi.org/10.1007/s11604-012-0087-2
doi: 10.1007/s11604-012-0087-2
pubmed: 22610876
Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, Kosuge T, Yamasaki S, Fukushima N, Sakamoto M (2002) Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer 95 (9):1931-1937. https://doi.org/10.1002/cncr.10892
doi: 10.1002/cncr.10892
pubmed: 12404287
Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ (2004) Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 28 (4):376-381. https://doi.org/10.1007/s00268-003-7308-x
doi: 10.1007/s00268-003-7308-x
pubmed: 15022021
Kang TW, Rhim H, Kim EY, Kim YS, Choi D, Lee WJ, Lim HK (2009) Percutaneous radiofrequency ablation for the hepatocellular carcinoma abutting the diaphragm: assessment of safety and therapeutic efficacy. Korean J Radiol 10 (1):34-42. https://doi.org/10.3348/kjr.2009.10.1.34
doi: 10.3348/kjr.2009.10.1.34
pubmed: 19182501
pmcid: 2647171
Lee IJ, Kim YI, Kim KW, Kim DH, Ryoo I, Lee MW, Chung JW (2012) Radiofrequency ablation combined with transcatheter arterial embolisation in rabbit liver: investigation of the ablation zone according to the time interval between the two therapies. The British journal of radiology 85 (1019):e987-994. https://doi.org/10.1259/bjr/90024696
doi: 10.1259/bjr/90024696
pubmed: 22674711
pmcid: 3500822
Moon H, Choi JE, Lee IJ, Kim TH, Kim SH, Ko YH, Kim HB, Nam BH, Park JW (2017) All-treatment array of hepatocellular carcinoma from initial diagnosis to death: observation of cumulative treatments. J Cancer Res Clin Oncol 143 (11):2327-2339. https://doi.org/10.1007/s00432-017-2480-9
doi: 10.1007/s00432-017-2480-9
pubmed: 28744575
pmcid: 5640756